Key result
Baseline SGLT2 inhibitor use is linked to over a 5-fold higher risk of severe DKA.
Why the study?
SGLT2 inhibitors have established cardiac and kidney benefits, but diabetic ketoacidosis is a rare complication associated with their use that entails significant morbidity and mortality.
Does baseline SGLT2 inhibitor use increase the severity of diabetic ketoacidosis in hospitalized patients with diabetes?
Observational (n=191)
No
Does baseline SGLT2 inhibitor use increase the severity of diabetic ketoacidosis in hospitalized patients with diabetes?
In patients hospitalized with diabetic ketoacidosis, baseline use of SGLT2 inhibitors is associated with a more severe biochemical presentation, characterized by a lower nadir pH and higher rates of severe DKA.
Answers are grounded in this paper and cite their sources.
May warrant closer monitoring for severe DKA in SGLT2 inhibitor users; hypothesis-generating association that leaves causal inference and practice change open.
AIMS: Sodium glucose cotransporter 2 inhibitors (SGLT2i) are commonly used glucose lowering agents with established cardiac and kidney benefits. Diabetic ketoacidosis (DKA) is a rare complication associated with their use, which entails significant morbidity and mortality. MATERIALS AND METHODS: This retrospective observational study included patients with diabetes (any) admitted with DKA to a large tertiary hospital. Demographic, clinical and laboratory data were extracted from electronic medical records. Outcomes included DKA severity as determined by nadir pH, duration of stay, need for intensive care (ICU) and inpatient mortality. RESULTS: Baseline SGLT2i use was documented in 27/191 patients (14.1%). SGLT2i users had lower nadir pH (7.08 ± 0.15 vs. 7.15 ± 0.12, p = 0.006) and were more likely to have severe DKA (29.6% vs. 12.2%, p = 0.007). After adjusting for multiple covariates, SGLT2i use remained independently associated with DKA severity. ICU admission and hospitalisation duration did not differ between the groups. Inpatient mortality occurred in 3/27 users and 3/164 non-users, while the composite outcome of mortality and/or ICU admission was similar (74.1% vs. 72.0%, p = 0.819). Findings remained consistent after excluding patients with new-onset diabetes. CONCLUSIONS: Among patients hospitalised with DKA in a large tertiary centre, SGLT2i use was associated with a more severe biochemical presentation, reflected by a lower nadir pH. The observed difference in inpatient mortality was based on few events and should be interpreted cautiously.
No takes yet. Share an insight, caveat, or question.
Naaman et al. (2026) conducted an observational in Diabetic ketoacidosis (n=191). SGLT2 inhibitors vs. SGLT2 inhibitor non-users was evaluated on Severity of DKA (categorical nadir pH) (Adjusted OR 5.48, 95% CI 1.81-16.64, p=0.003). SGLT2 inhibitor use in patients hospitalized with diabetic ketoacidosis was independently associated with a more severe biochemical presentation and a higher risk of severe DKA.
Synapse has enriched 10 related papers. Consider them for comparative context: